Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino

La Enfermedad mixomatosa de la válvula mitral es la patología cardiaca más importante en la medicina cardiovascular de pequeños animales, particularmente en los perros. Debido a que la MMVD es un ejemplo de una enfermedad crónica que progresa de leve a grave a lo largo de los años, las estrategias d...

Full description

Autores:: Merchán Castellanos, Helbert Darío

Tipo de recurso:: Trabajo de grado de pregrado

Fecha de publicación:: 2018

Institución:: Universidad Cooperativa de Colombia

Repositorio:: Repositorio UCC

Idioma:

id	COOPER2_8587e51ce3fd93896e67705ffffadb9b
oai_identifier_str	oai:repository.ucc.edu.co:20.500.12494/8961
network_acronym_str	COOPER2
network_name_str	Repositorio UCC
repository_id_str
dc.title.spa.fl_str_mv	Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino
title	Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino
spellingShingle	Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino Enfermedad Valvular Degeneración Mixomatosa Válvula Mitral Tratamiento TG 2018 MVZ 8961
title_short	Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino
title_full	Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino
title_fullStr	Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino
title_full_unstemmed	Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino
title_sort	Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino
dc.creator.fl_str_mv	Merchán Castellanos, Helbert Darío
dc.contributor.advisor.none.fl_str_mv	Sánchez Pico, Favio
dc.contributor.author.none.fl_str_mv	Merchán Castellanos, Helbert Darío
dc.subject.spa.fl_str_mv	Enfermedad Valvular Degeneración Mixomatosa Válvula Mitral Tratamiento
topic	Enfermedad Valvular Degeneración Mixomatosa Válvula Mitral Tratamiento TG 2018 MVZ 8961
dc.subject.classification.spa.fl_str_mv	TG 2018 MVZ 8961
description	La Enfermedad mixomatosa de la válvula mitral es la patología cardiaca más importante en la medicina cardiovascular de pequeños animales, particularmente en los perros. Debido a que la MMVD es un ejemplo de una enfermedad crónica que progresa de leve a grave a lo largo de los años, las estrategias de tratamiento cambian con la etapa de la enfermedad. El manejo exitoso de la enfermedad cardíaca requiere terapia oportuna y multimodal, con el objetivo de mantener la calidad de vida para el paciente y el propietario.
publishDate	2018
dc.date.issued.none.fl_str_mv	2018
dc.date.accessioned.none.fl_str_mv	2019-05-14T12:36:24Z
dc.date.available.none.fl_str_mv	2019-05-14T12:36:24Z
dc.type.none.fl_str_mv	Trabajo de grado - Pregrado
dc.type.coar.none.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/bachelorThesis
dc.type.version.none.fl_str_mv	info:eu-repo/semantics/acceptedVersion
format	http://purl.org/coar/resource_type/c_7a1f
status_str	acceptedVersion
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/20.500.12494/8961
dc.identifier.bibliographicCitation.spa.fl_str_mv	Merchán Castellanos, H. D. (2018). Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino. (Trabajo de pregrado) Recuperado de: http://repository.ucc.edu.co/handle/ucc/8961
url	https://hdl.handle.net/20.500.12494/8961
identifier_str_mv	Merchán Castellanos, H. D. (2018). Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino. (Trabajo de pregrado) Recuperado de: http://repository.ucc.edu.co/handle/ucc/8961
dc.relation.references.spa.fl_str_mv	Borgarelli M, Buchanan JW. Historical review, epidemiology and natural history of degenerative mitral valve disease. J Vet Cardiol. 1 de marzo de 2012;14(1):93-101. Mattin MJ, Boswood A, Church DB, McGreevy PD, O’Neill DG, Thomson PC, et al. Degenerative mitral valve disease: Survival of dogs attending primary-care practice in England. Prev Vet Med. 1 de diciembre de 2015;122(4):436-42 Parker HG, Kilroy-Glynn P. Myxomatous mitral valve disease in dogs: Does size matter? J Vet Cardiol. 1 de marzo de 2012;14(1):19-29. Kim H-T, Han S-M, Song W-J, Kim B, Choi M, Yoon J, et al. Retrospective study of degenerative mitral valve disease in small-breed dogs: survival and prognostic variables. J Vet Sci. septiembre de 2017;18(3):369-76 Atkins CE, Häggström J. Pharmacologic management of myxomatous mitral valve disease in dogs. J Vet Cardiol. 1 de marzo de 2012;14(1):165-84. Burchell RK, Schoeman J. Medical management of myxomatous mitral valve disease: An evidence-based veterinary medicine approach. J South Afr Vet Assoc Pretoria. 2014;85(1):1-7. Cardona Arias JA, Higuita Gutiérrez LF, Ríos Osorio LA. Revisiones sistemáticas de la literatura científica: La investigación teórica como principio para el desarrollo de la ciencia básica y aplicada [Internet]. Universidad Cooperativa de Colombia; 2016 [citado 29 de marzo de 2018]. Disponible en: http://ediciones.ucc.edu.co/index.php/ucc/catalog/book/24 Gordon SG, Saunders AB, Wesselowski SR. Asymptomatic Canine Degenerative Valve Disease: Current and Future Therapies. Vet Clin North Am Small Anim Pract. 1 de septiembre de 2017;47(5):955-75. Fox PR. Pathology of myxomatous mitral valve disease in the dog. J Vet Cardiol. 1 de marzo de 2012;14(1):103-26. Markby G, Summers KM, MacRae VE, Del-Pozo J, Corcoran BM. Myxomatous Degeneration of the Canine Mitral Valve: From Gross Changes to Molecular Events. J Comp Pathol. 1 de mayo de 2017;156(4):371-83 Orton EC, Lacerda CMR, MacLea HB. Signaling pathways in mitral valve degeneration. J Vet Cardiol. 1 de marzo de 2012;14(1):7-17 Han RI, Clark CH, Black A, French A, Culshaw GJ, Kempson SA, et al. Morphological changes to endothelial and interstitial cells and to the extra-cellular matrix in canine myxomatous mitral valve disease (endocardiosis). Vet J. 1 de agosto de 2013;197(2):388-94 Jung SW, Sun W, Griffiths LG, Kittleson MD. Atrial Fibrillation as a Prognostic Indicator in Medium to Large-Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure. J Vet Intern Med. febrero de 2016;30(1):51-7. KIJTAWORNRAT A, KOMOLVANICH S, SAENGKLUB N, PIRINTR P, BOONPALA P, BURANAKARL C. Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration. J Vet Med Sci. abril de 2017;79(4):788-94. Meurs KM, Friedenberg SG, Williams B, Keene BW, Atkins CE, Adin D, et al. Evaluation of genes associated with human myxomatous mitral valve disease in dogs with familial myxomatous mitral valve degeneration. Vet J. 1 de febrero de 2018;232:16-9. Kohkayasit P, Surachetpong S. Short Term Echocardiographic and Clinical Effects of Ramipril on Dogs with Asymptomatic Degenerative Mitral Valve Disease. Thai J Vet Med Bangk. 2013;43(3):337-46. Burchell RK, Schoeman J. Advances in the Understanding of the Pathogenesis, Progression and Diagnosis of Myxomatous Mitral Valve Disease in Dogs. J South Afr Vet Assoc Pretoria. 2014;85(1):1-5. Orton EC. Mitral valve degeneration: Still more questions than answers. J Vet Cardiol. 1 de marzo de 2012;14(1):3-5. Connell PS, Han RI, Grande-Allen KJ. Differentiating the aging of the mitral valve from human and canine myxomatous degeneration. J Vet Cardiol. 1 de marzo de 2012;14(1):31-45 Waxman AS, Kornreich BG, Gould RA, Sydney Moïse N, Butcher JT. Interactions between TGFβ1 and cyclic strain in modulation of myofibroblastic differentiation of canine mitral valve interstitial cells in 3D culture. J Vet Cardiol. 1 de marzo de 2012;14(1):211-21. Lacerda CMR, MacLea HB, Kisiday JD, Orton EC. Static and cyclic tensile strain induce myxomatous effector proteins and serotonin in canine mitral valves. J Vet Cardiol. 1 de marzo de 2012;14(1):223-30 Wesselowski S, Borgarelli M, Menciotti G, Abbott J. Echocardiographic anatomy of the mitral valve in healthy dogs and dogs with myxomatous mitral valve disease. J Vet Cardiol. 1 de junio de 2015;17(2):97-106 Borgarelli M, Lanz O, Pavlisko N, Abbott JA, Menciotti G, Aherne M, et al. Mitral valve repair in dogs using an ePTFE chordal implantation device: a pilot study. J Vet Cardiol. 1 de junio de 2017;19(3):256-67. Suzuki S, Fukushima R, Ishikawa T, Yamamoto Y, Hamabe L, Kim S, et al. Comparative effects of amlodipine and benazepril on Left Atrial Pressure in Dogs with experimentally-induced Mitral Valve Regurgitation. BMC Vet Res Lond. 2012;8:166 äck M, Pizarro R, Clavel M-A. Biomarkers in Mitral Regurgitation. Prog Cardiovasc Dis. 1 de noviembre de 2017;60(3):334-41. Saunders AB. The Diagnosis and Management of Age-Related Veterinary Cardiovascular Disease. Vet Clin North Am Small Anim Pract. 1 de julio de 2012;42(4):655-68. Sargent J, Muzzi R, Mukherjee R, Somarathne S, Schranz K, Stephenson H, et al. Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease. J Vet Cardiol. 1 de marzo de 2015;17(1):1-12 Ahmed MI, Aban I, Lloyd SG, Gupta H, Howard G, Inusah S, et al. A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. J Am Coll Cardiol. 28 de agosto de 2012;60(9):833-8. Hezzell MJ, Boswood A, López-Alvarez J, Lötter N, Elliott J. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone—a pilot study. J Vet Cardiol. 1 de agosto de 2017;19(4):325-38. Dillon AR, Dell’Italia LJ, Tillson M, Killingsworth C, Denney T, Hathcock J, et al. Left ventricular remodeling in preclinical experimental mitral regurgitation of dogs. J Vet Cardiol. 1 de marzo de 2012;14(1):73-92 Chetboul V, Pouchelon J ‐L., Menard J, Blanc J, Desquilbet L, Petit A, et al. Short‐Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study. J Vet Intern Med. 2017;31(6):1629-42. Hezzell MJ, Boswood A, Moonarmart W, Elliott J. Selected echocardiographic variables change more rapidly in dogs that die from myxomatous mitral valve disease. J Vet Cardiol. 1 de marzo de 2012;14(1):269-79. PIRINTR P, SAENGKLUB N, LIMPRASUTR V, SAWANGKOON S, KIJTAWORNRAT A. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration. J Vet Med Sci. septiembre de 2017;79(9):1480-8. Ames MK, Atkins CE, Eriksson A, Hess AM. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease. J Vet Cardiol. 1 de junio de 2017;19(3):218-27. atel BM, Mehta AA. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. Eur J Pharmacol. 15 de diciembre de 2012;697(1):1-12. Mentz RJ, Bakris GL, Waeber B, McMurray JJV, Gheorghiade M, Ruilope LM, et al. The past, present and future of renin–angiotensin aldosterone system inhibition. Int J Cardiol. 1 de septiembre de 2013;167(5):1677-87. Chompoosan C, Buranakarl C, Chaiyabutr N, Chansaisakorn W. Decreased sympathetic tone after short-term treatment with enalapril in dogs with mild chronic mitral valve disease. Res Vet Sci. 1 de abril de 2014;96(2):347-54. Trafny DJ, Freeman LM, Bulmer BJ, MacGregor JM, Rush JE, Meurs KM, et al. Auscultatory, echocardiographic, biochemical, nutritional, and environmental characteristics of mitral valve disease in Norfolk terriers. J Vet Cardiol. 1 de marzo de 2012;14(1):261-7 Larsson MHMA, Schwartz DS, Goldfeder GT, Oliveira VMC de, Itikawa PH, Mazini AM, et al. Pimobendan Improves Clinical Signs in Short Term Compared to Digoxin or Placebo in Dogs with Heart Failure Due to Chronic Degenerative Mitral Valve Disease. Acta Sci Vet. 2014;42(1):1-7. Peddle GD, Singletary GE, Reynolds CA, Trafny DJ, Machen MC, Oyama MA. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease. J Vet Cardiol. 1 de marzo de 2012;14(1):253-9. Atkins CE, Lantis AC, Ames MK, Gardner SY. Utility of urinary aldosterone measurement in quantitating RAAS activation. J Vet Pharmacol Ther. octubre de 2012;35(5):512-5; author reply 516-518. Lefebvre HP, Ollivier E, Atkins CE, Combes B, Concordet D, Kaltsatos V, et al. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study. J Vet Intern Med. octubre de 2013;27(5):1083-91. Suzuki S, Fukushima R, Yamamoto Y, Ishikawa T, Hamabe L, Kim S, et al. Comparative effect of carperitide and furosemide on left atrial pressure in dogs with experimentally induced mitral valve regurgitation. J Vet Intern Med. octubre de 2013;27(5):1097-104 Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, et al. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure. J Vet Intern Med. diciembre de 2013;27(6):1452-62. Cunningham SM, Rush JE, Freeman LM. Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease. J Vet Intern Med. agosto de 2013;27(4):985-9. DeFrancesco TC. Management of Cardiac Emergencies in Small Animals. Vet Clin North Am Small Anim Pract. 1 de julio de 2013;43(4):817-42. Ebisawa T, Ohta Y, Funayama M, Yamano S, Mizuno M, Mizuno T, et al. Plasma atrial natriuretic peptide is an early diagnosis and disease severity marker of myxomatous mitral valve disease in dogs. Res Vet Sci. 1 de junio de 2013;94(3):717-21. Rhinehart JD, Schober KE, Scansen BA, Yildiz V, Bonagura JD. Effect of Body Position, Exercise, and Sedation on Estimation of Pulmonary Artery Pressure in Dogs with Degenerative Atrioventricular Valve Disease. J Vet Intern Med. 2017;31(6):1611-21. Munín MA, Thierer J, Goerner MS, Raggio IM, Godia J, Ortega J, et al. Three-dimensional Echocardiography in Characterization of Degenerative Mitral Valve Disease. Rev Argent Cardiol. 2016;84(4):317-22. Jones ID, Luis Fuentes V, Boswood A, Hezzell MJ, Wrigglesworth D, Mateus A, et al. Ultrasonographic measurement of flow-mediated vasodilation in dogs with chronic valvular disease. J Vet Cardiol. 1 de marzo de 2012;14(1):203-10 LeBlanc N, Scollan K, Sisson D. Quantitative evaluation of left atrial volume and function by one-dimensional, two-dimensional, and three-dimensional echocardiography in a population of normal dogs. J Vet Cardiol. 1 de diciembre de 2016;18(4):336-49 Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, et al. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. J Vet Intern Med. 2018;32(1):72-85. Buzzano O, Graziano A, Barrios J, Lightowler C. Efecto de la asociación de tres drogas en el tratamiento de la insuficiencia cardiaca congestiva en perros con mixomatosis mitral. InVet. 2015;17(1):7-15 Silva AC, Oberlender G, Mantovani MM, Muzzi R a. L, Pereira LJ, Zangeronimo MG. Efficacy of sildenafil therapy for pulmonary hypertension in dogs: a systematic review. Arch Med Vet. 2014;46(2):277-87. KuKanich B. Geriatric Veterinary Pharmacology. Vet Clin North Am Small Anim Pract. 1 de julio de 2012;42(4):631-42.
dc.rights.license.none.fl_str_mv	Atribución – Sin Derivar
dc.rights.accessrights.none.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.coar.none.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	Atribución – Sin Derivar http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.extent.spa.fl_str_mv	116 p.
dc.publisher.spa.fl_str_mv	Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Medicina Veterinaría y Zootecnia, Bucaramanga
dc.publisher.program.spa.fl_str_mv	Medicina veterinaria y zootecnia
dc.publisher.place.spa.fl_str_mv	Bucaramanga
institution	Universidad Cooperativa de Colombia
bitstream.url.fl_str_mv	https://repository.ucc.edu.co/bitstreams/40249110-9e79-48dd-9c7d-820fc85e5e8e/download https://repository.ucc.edu.co/bitstreams/3402315e-4ee1-4d88-814a-c805077eef33/download https://repository.ucc.edu.co/bitstreams/bb8c0b7c-1195-4559-8df4-2238865650d9/download https://repository.ucc.edu.co/bitstreams/0f28c6b8-45d2-4ffd-8be3-50366a0c49fb/download https://repository.ucc.edu.co/bitstreams/81caf459-390e-49eb-8d5e-1f3d35e5ef45/download https://repository.ucc.edu.co/bitstreams/9b1455d6-aebd-41ef-82da-88d9c7464392/download https://repository.ucc.edu.co/bitstreams/c0648ba8-15ae-469e-84c4-6cadc0d3108c/download
bitstream.checksum.fl_str_mv	3bce4f7ab09dfc588f126e1e36e98a45 c57e79aa9b95df196766ef496bf5ae44 59b3f2360897c30b8b5d3652470c8086 f5333f5a509a2221474160183514e4be e059fb79ad971837b829f884cc124a28 4f3c50c2a4aaee244a3b7085c4c071d5 e1c06d85ae7b8b032bef47e42e4c08f9
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional Universidad Cooperativa de Colombia
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1814247142859997184
spelling	Sánchez Pico, FavioMerchán Castellanos, Helbert Darío2019-05-14T12:36:24Z2019-05-14T12:36:24Z2018https://hdl.handle.net/20.500.12494/8961Merchán Castellanos, H. D. (2018). Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino. (Trabajo de pregrado) Recuperado de: http://repository.ucc.edu.co/handle/ucc/8961La Enfermedad mixomatosa de la válvula mitral es la patología cardiaca más importante en la medicina cardiovascular de pequeños animales, particularmente en los perros. Debido a que la MMVD es un ejemplo de una enfermedad crónica que progresa de leve a grave a lo largo de los años, las estrategias de tratamiento cambian con la etapa de la enfermedad. El manejo exitoso de la enfermedad cardíaca requiere terapia oportuna y multimodal, con el objetivo de mantener la calidad de vida para el paciente y el propietario.Myxomatous mitral valve disease is the most important cardiac pathology in cardiovascular medicine of small animals, particularly in dogs. Because MMVD is an example of a chronic disease that progresses from mild to severe over the years, treatment strategies change with the stage of the disease. The successful management of heart disease requires timely and multimodal therapy, with the aim of maintaining the quality of life for the patient and the owner.Resumen. -- Introducción. -- Metodología. -- Resultados. -- Palabras clave. -- Abstract. -- Introduction. -- Methodology. -- Results. -- Keywords. -- Descripción del proyecto de investigación: Planteamiento del problema de investigación y su justificación en términos de necesidades y pertinencia. -- Justificación. -- Objetivos. -- Objetivo general. -- Realizar una búsqueda sistemática de literatura sobre los planes terapéuticos y el manejo clínico de la Enfermedad de la válvula mitral mixomatosa en perros. -- Objetivos específicos. -- Planteamiento del problema. -- Diseño de la investigación. -- Variables. -- Variable independiente. -- Universo. -- Población de estudio. -- Criterios para el estudio. -- Criterios de inclusión. -- Criterios de exclusión. -- Resultados. -- Conflicto de intereses. -- Cronograma de actividades.helbert.merchanc@campusucc.edu.co116 p. Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Medicina Veterinaría y Zootecnia, BucaramangaMedicina veterinaria y zootecniaBucaramangaEnfermedad ValvularDegeneración MixomatosaVálvula MitralTratamientoTG 2018 MVZ 8961Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente caninoTrabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/acceptedVersionAtribución – Sin Derivarinfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Borgarelli M, Buchanan JW. Historical review, epidemiology and natural history of degenerative mitral valve disease. J Vet Cardiol. 1 de marzo de 2012;14(1):93-101.Mattin MJ, Boswood A, Church DB, McGreevy PD, O’Neill DG, Thomson PC, et al. Degenerative mitral valve disease: Survival of dogs attending primary-care practice in England. Prev Vet Med. 1 de diciembre de 2015;122(4):436-42Parker HG, Kilroy-Glynn P. Myxomatous mitral valve disease in dogs: Does size matter? J Vet Cardiol. 1 de marzo de 2012;14(1):19-29.Kim H-T, Han S-M, Song W-J, Kim B, Choi M, Yoon J, et al. Retrospective study of degenerative mitral valve disease in small-breed dogs: survival and prognostic variables. J Vet Sci. septiembre de 2017;18(3):369-76Atkins CE, Häggström J. Pharmacologic management of myxomatous mitral valve disease in dogs. J Vet Cardiol. 1 de marzo de 2012;14(1):165-84.Burchell RK, Schoeman J. Medical management of myxomatous mitral valve disease: An evidence-based veterinary medicine approach. J South Afr Vet Assoc Pretoria. 2014;85(1):1-7.Cardona Arias JA, Higuita Gutiérrez LF, Ríos Osorio LA. Revisiones sistemáticas de la literatura científica: La investigación teórica como principio para el desarrollo de la ciencia básica y aplicada [Internet]. Universidad Cooperativa de Colombia; 2016 [citado 29 de marzo de 2018]. Disponible en: http://ediciones.ucc.edu.co/index.php/ucc/catalog/book/24Gordon SG, Saunders AB, Wesselowski SR. Asymptomatic Canine Degenerative Valve Disease: Current and Future Therapies. Vet Clin North Am Small Anim Pract. 1 de septiembre de 2017;47(5):955-75.Fox PR. Pathology of myxomatous mitral valve disease in the dog. J Vet Cardiol. 1 de marzo de 2012;14(1):103-26.Markby G, Summers KM, MacRae VE, Del-Pozo J, Corcoran BM. Myxomatous Degeneration of the Canine Mitral Valve: From Gross Changes to Molecular Events. J Comp Pathol. 1 de mayo de 2017;156(4):371-83Orton EC, Lacerda CMR, MacLea HB. Signaling pathways in mitral valve degeneration. J Vet Cardiol. 1 de marzo de 2012;14(1):7-17Han RI, Clark CH, Black A, French A, Culshaw GJ, Kempson SA, et al. Morphological changes to endothelial and interstitial cells and to the extra-cellular matrix in canine myxomatous mitral valve disease (endocardiosis). Vet J. 1 de agosto de 2013;197(2):388-94Jung SW, Sun W, Griffiths LG, Kittleson MD. Atrial Fibrillation as a Prognostic Indicator in Medium to Large-Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure. J Vet Intern Med. febrero de 2016;30(1):51-7.KIJTAWORNRAT A, KOMOLVANICH S, SAENGKLUB N, PIRINTR P, BOONPALA P, BURANAKARL C. Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration. J Vet Med Sci. abril de 2017;79(4):788-94.Meurs KM, Friedenberg SG, Williams B, Keene BW, Atkins CE, Adin D, et al. Evaluation of genes associated with human myxomatous mitral valve disease in dogs with familial myxomatous mitral valve degeneration. Vet J. 1 de febrero de 2018;232:16-9.Kohkayasit P, Surachetpong S. Short Term Echocardiographic and Clinical Effects of Ramipril on Dogs with Asymptomatic Degenerative Mitral Valve Disease. Thai J Vet Med Bangk. 2013;43(3):337-46.Burchell RK, Schoeman J. Advances in the Understanding of the Pathogenesis, Progression and Diagnosis of Myxomatous Mitral Valve Disease in Dogs. J South Afr Vet Assoc Pretoria. 2014;85(1):1-5.Orton EC. Mitral valve degeneration: Still more questions than answers. J Vet Cardiol. 1 de marzo de 2012;14(1):3-5.Connell PS, Han RI, Grande-Allen KJ. Differentiating the aging of the mitral valve from human and canine myxomatous degeneration. J Vet Cardiol. 1 de marzo de 2012;14(1):31-45Waxman AS, Kornreich BG, Gould RA, Sydney Moïse N, Butcher JT. Interactions between TGFβ1 and cyclic strain in modulation of myofibroblastic differentiation of canine mitral valve interstitial cells in 3D culture. J Vet Cardiol. 1 de marzo de 2012;14(1):211-21.Lacerda CMR, MacLea HB, Kisiday JD, Orton EC. Static and cyclic tensile strain induce myxomatous effector proteins and serotonin in canine mitral valves. J Vet Cardiol. 1 de marzo de 2012;14(1):223-30Wesselowski S, Borgarelli M, Menciotti G, Abbott J. Echocardiographic anatomy of the mitral valve in healthy dogs and dogs with myxomatous mitral valve disease. J Vet Cardiol. 1 de junio de 2015;17(2):97-106Borgarelli M, Lanz O, Pavlisko N, Abbott JA, Menciotti G, Aherne M, et al. Mitral valve repair in dogs using an ePTFE chordal implantation device: a pilot study. J Vet Cardiol. 1 de junio de 2017;19(3):256-67.Suzuki S, Fukushima R, Ishikawa T, Yamamoto Y, Hamabe L, Kim S, et al. Comparative effects of amlodipine and benazepril on Left Atrial Pressure in Dogs with experimentally-induced Mitral Valve Regurgitation. BMC Vet Res Lond. 2012;8:166äck M, Pizarro R, Clavel M-A. Biomarkers in Mitral Regurgitation. Prog Cardiovasc Dis. 1 de noviembre de 2017;60(3):334-41.Saunders AB. The Diagnosis and Management of Age-Related Veterinary Cardiovascular Disease. Vet Clin North Am Small Anim Pract. 1 de julio de 2012;42(4):655-68.Sargent J, Muzzi R, Mukherjee R, Somarathne S, Schranz K, Stephenson H, et al. Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease. J Vet Cardiol. 1 de marzo de 2015;17(1):1-12Ahmed MI, Aban I, Lloyd SG, Gupta H, Howard G, Inusah S, et al. A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. J Am Coll Cardiol. 28 de agosto de 2012;60(9):833-8.Hezzell MJ, Boswood A, López-Alvarez J, Lötter N, Elliott J. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone—a pilot study. J Vet Cardiol. 1 de agosto de 2017;19(4):325-38.Dillon AR, Dell’Italia LJ, Tillson M, Killingsworth C, Denney T, Hathcock J, et al. Left ventricular remodeling in preclinical experimental mitral regurgitation of dogs. J Vet Cardiol. 1 de marzo de 2012;14(1):73-92Chetboul V, Pouchelon J ‐L., Menard J, Blanc J, Desquilbet L, Petit A, et al. Short‐Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study. J Vet Intern Med. 2017;31(6):1629-42.Hezzell MJ, Boswood A, Moonarmart W, Elliott J. Selected echocardiographic variables change more rapidly in dogs that die from myxomatous mitral valve disease. J Vet Cardiol. 1 de marzo de 2012;14(1):269-79.PIRINTR P, SAENGKLUB N, LIMPRASUTR V, SAWANGKOON S, KIJTAWORNRAT A. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration. J Vet Med Sci. septiembre de 2017;79(9):1480-8.Ames MK, Atkins CE, Eriksson A, Hess AM. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease. J Vet Cardiol. 1 de junio de 2017;19(3):218-27.atel BM, Mehta AA. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. Eur J Pharmacol. 15 de diciembre de 2012;697(1):1-12.Mentz RJ, Bakris GL, Waeber B, McMurray JJV, Gheorghiade M, Ruilope LM, et al. The past, present and future of renin–angiotensin aldosterone system inhibition. Int J Cardiol. 1 de septiembre de 2013;167(5):1677-87.Chompoosan C, Buranakarl C, Chaiyabutr N, Chansaisakorn W. Decreased sympathetic tone after short-term treatment with enalapril in dogs with mild chronic mitral valve disease. Res Vet Sci. 1 de abril de 2014;96(2):347-54.Trafny DJ, Freeman LM, Bulmer BJ, MacGregor JM, Rush JE, Meurs KM, et al. Auscultatory, echocardiographic, biochemical, nutritional, and environmental characteristics of mitral valve disease in Norfolk terriers. J Vet Cardiol. 1 de marzo de 2012;14(1):261-7Larsson MHMA, Schwartz DS, Goldfeder GT, Oliveira VMC de, Itikawa PH, Mazini AM, et al. Pimobendan Improves Clinical Signs in Short Term Compared to Digoxin or Placebo in Dogs with Heart Failure Due to Chronic Degenerative Mitral Valve Disease. Acta Sci Vet. 2014;42(1):1-7.Peddle GD, Singletary GE, Reynolds CA, Trafny DJ, Machen MC, Oyama MA. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease. J Vet Cardiol. 1 de marzo de 2012;14(1):253-9.Atkins CE, Lantis AC, Ames MK, Gardner SY. Utility of urinary aldosterone measurement in quantitating RAAS activation. J Vet Pharmacol Ther. octubre de 2012;35(5):512-5; author reply 516-518.Lefebvre HP, Ollivier E, Atkins CE, Combes B, Concordet D, Kaltsatos V, et al. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study. J Vet Intern Med. octubre de 2013;27(5):1083-91.Suzuki S, Fukushima R, Yamamoto Y, Ishikawa T, Hamabe L, Kim S, et al. Comparative effect of carperitide and furosemide on left atrial pressure in dogs with experimentally induced mitral valve regurgitation. J Vet Intern Med. octubre de 2013;27(5):1097-104Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, et al. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure. J Vet Intern Med. diciembre de 2013;27(6):1452-62.Cunningham SM, Rush JE, Freeman LM. Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease. J Vet Intern Med. agosto de 2013;27(4):985-9.DeFrancesco TC. Management of Cardiac Emergencies in Small Animals. Vet Clin North Am Small Anim Pract. 1 de julio de 2013;43(4):817-42.Ebisawa T, Ohta Y, Funayama M, Yamano S, Mizuno M, Mizuno T, et al. Plasma atrial natriuretic peptide is an early diagnosis and disease severity marker of myxomatous mitral valve disease in dogs. Res Vet Sci. 1 de junio de 2013;94(3):717-21.Rhinehart JD, Schober KE, Scansen BA, Yildiz V, Bonagura JD. Effect of Body Position, Exercise, and Sedation on Estimation of Pulmonary Artery Pressure in Dogs with Degenerative Atrioventricular Valve Disease. J Vet Intern Med. 2017;31(6):1611-21.Munín MA, Thierer J, Goerner MS, Raggio IM, Godia J, Ortega J, et al. Three-dimensional Echocardiography in Characterization of Degenerative Mitral Valve Disease. Rev Argent Cardiol. 2016;84(4):317-22.Jones ID, Luis Fuentes V, Boswood A, Hezzell MJ, Wrigglesworth D, Mateus A, et al. Ultrasonographic measurement of flow-mediated vasodilation in dogs with chronic valvular disease. J Vet Cardiol. 1 de marzo de 2012;14(1):203-10LeBlanc N, Scollan K, Sisson D. Quantitative evaluation of left atrial volume and function by one-dimensional, two-dimensional, and three-dimensional echocardiography in a population of normal dogs. J Vet Cardiol. 1 de diciembre de 2016;18(4):336-49Boswood A, Gordon SG, Häggström J, Wess G, Stepien RL, Oyama MA, et al. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. J Vet Intern Med. 2018;32(1):72-85.Buzzano O, Graziano A, Barrios J, Lightowler C. Efecto de la asociación de tres drogas en el tratamiento de la insuficiencia cardiaca congestiva en perros con mixomatosis mitral. InVet. 2015;17(1):7-15Silva AC, Oberlender G, Mantovani MM, Muzzi R a. L, Pereira LJ, Zangeronimo MG. Efficacy of sildenafil therapy for pulmonary hypertension in dogs: a systematic review. Arch Med Vet. 2014;46(2):277-87.KuKanich B. Geriatric Veterinary Pharmacology. Vet Clin North Am Small Anim Pract. 1 de julio de 2012;42(4):631-42.PublicationLICENSElicense.txtlicense.txttext/plain; charset=utf-84334https://repository.ucc.edu.co/bitstreams/40249110-9e79-48dd-9c7d-820fc85e5e8e/download3bce4f7ab09dfc588f126e1e36e98a45MD53ORIGINAL2018_enfermedad_mixomatosa.pdf2018_enfermedad_mixomatosa.pdf2018_enfermedad_mixomatosaapplication/pdf2439379https://repository.ucc.edu.co/bitstreams/3402315e-4ee1-4d88-814a-c805077eef33/downloadc57e79aa9b95df196766ef496bf5ae44MD512018_enfermedad_mixomatosa_licenciadeuso.pdf2018_enfermedad_mixomatosa_licenciadeuso.pdf2018_enfermedad_mixomatosa_licenciadeusoapplication/pdf348627https://repository.ucc.edu.co/bitstreams/bb8c0b7c-1195-4559-8df4-2238865650d9/download59b3f2360897c30b8b5d3652470c8086MD52THUMBNAIL2018_enfermedad_mixomatosa.pdf.jpg2018_enfermedad_mixomatosa.pdf.jpgGenerated Thumbnailimage/jpeg3330https://repository.ucc.edu.co/bitstreams/0f28c6b8-45d2-4ffd-8be3-50366a0c49fb/downloadf5333f5a509a2221474160183514e4beMD542018_enfermedad_mixomatosa_licenciadeuso.pdf.jpg2018_enfermedad_mixomatosa_licenciadeuso.pdf.jpgGenerated Thumbnailimage/jpeg4696https://repository.ucc.edu.co/bitstreams/81caf459-390e-49eb-8d5e-1f3d35e5ef45/downloade059fb79ad971837b829f884cc124a28MD55TEXT2018_enfermedad_mixomatosa.pdf.txt2018_enfermedad_mixomatosa.pdf.txtExtracted texttext/plain101999https://repository.ucc.edu.co/bitstreams/9b1455d6-aebd-41ef-82da-88d9c7464392/download4f3c50c2a4aaee244a3b7085c4c071d5MD562018_enfermedad_mixomatosa_licenciadeuso.pdf.txt2018_enfermedad_mixomatosa_licenciadeuso.pdf.txtExtracted texttext/plain2https://repository.ucc.edu.co/bitstreams/c0648ba8-15ae-469e-84c4-6cadc0d3108c/downloade1c06d85ae7b8b032bef47e42e4c08f9MD5720.500.12494/8961oai:repository.ucc.edu.co:20.500.12494/89612024-08-09 12:39:14.545open.accesshttps://repository.ucc.edu.coRepositorio Institucional Universidad Cooperativa de Colombiabdigital@metabiblioteca.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

Enfermedad mixomatosa de la válvula mitral; manejo clínico y plan terapéutico del paciente canino

Publicaciones similares